Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the framingham offspring population

被引:3
作者
Welty, FK
Mittleman, MA
Wilson, PWF
Sutherland, PA
Matheney, TH
Lipinska, I
Muller, JE
Levy, D
Tofler, GH
机构
[1] HARVARD UNIV, SCH MED,BETH ISRAEL DEACONESS MED CTR, INST PREVENT CARDIOVASC DIS,CARDIOVASC DIV, BOSTON, MA USA
[2] FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA USA
关键词
cholesterol; fibrinogen; lipids; plasminogen activator inhibitor; von Willebrand factor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Given the importance of thrombosis in causation of acute coronary syndromes, it is possible that the beneficial effect of low lipid levels on the risk of coronary events is achieved by lowering thrombotic potential of the blood. Hypobetalipoproteinemia is characterized by plasma concentrations of apolipoprotein B and LDL cholesterol that are one third of those observed in the general population. The aim of this study was to utilize subjects with hypobetalipoproteinemia to examine the relation between thrombotic potential and low levels of LDL cholesterol. Method and Results Hemostatic risk factors were measured in 1878 individuals (1003 women and 875 men) participating in cycle 5 of the Framingham Offspring Study. The subjects were divided into five groups on the basis of LDL cholesterol level. Subjects with hypobetalipoproteinemia (LDL cholesterol <70 mg/dL) had the lowest levels of fibrinogen, plasminogen activator inhibitor-1 antigen, and tissue plasminogen activator antigen. As LDL cholesterol increased, there was a significant increase in the levels of the hemostatic risk factors, with the exception of von Willebrand factor antigen. Adjustment with multivariate regression analyses for the covariates age, sex, body mass index, diabetes mellitus, smoking, alcohol intake, triglyceride level, and use of antihypertensive medication did not materially alter the results. Conclusions Decreasing levels of LDL cholesterol are associated with decreasing levels of hemostatic risk factors. Subjects with hypobetalipoproteinemia have the lowest levels of hemostatic risk factors and may be protected against thrombotic complications of atherosclerotic cardiovascular disease because of reduced thrombotic potential. One mechanism by which lipid-lowering therapy may decrease clinical cardiac events is through a reduction in thrombotic tendency.
引用
收藏
页码:825 / 830
页数:6
相关论文
共 68 条
  • [1] ALDERMAN E, 1991, CIRCULATION S2, V84, P140
  • [2] ANDERSEN P, 1990, THROMB HAEMOSTASIS, V63, P174
  • [3] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS
    BLANKENHORN, DH
    NESSIM, SA
    JOHNSON, RL
    SANMARCO, ME
    AZEN, SP
    CASHINHEMPHILL, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23): : 3233 - 3240
  • [4] EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY
    BRENSIKE, JF
    LEVY, RI
    KELSEY, SF
    PASSAMANI, ER
    RICHARDSON, JM
    LOH, IK
    STONE, NJ
    ALDRICH, RF
    BATTAGLINI, JW
    MORIARTY, DJ
    FISHER, MR
    FRIEDMAN, L
    FRIEDEWALD, W
    DETRE, KM
    EPSTEIN, SE
    [J]. CIRCULATION, 1984, 69 (02) : 313 - 324
  • [5] REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B
    BROWN, G
    ALBERS, JJ
    FISHER, LD
    SCHAEFER, SM
    LIN, JT
    KAPLAN, C
    ZHAO, XQ
    BISSON, BD
    FITZPATRICK, VF
    DODGE, HT
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) : 1289 - 1298
  • [6] ATTENUATION OF THE SYNTHESIS OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 BY NIACIN - A POTENTIAL LINK BETWEEN LIPID-LOWERING AND FIBRINOLYSIS
    BROWN, SL
    SOBEL, BE
    FUJII, S
    [J]. CIRCULATION, 1995, 92 (04) : 767 - 772
  • [7] EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH)
    BUCHWALD, H
    VARCO, RL
    MATTS, JP
    LONG, JM
    FITCH, LL
    CAMPBELL, GS
    PEARCE, MB
    YELLIN, AE
    EDMISTON, WA
    SMINK, RD
    SAWIN, HS
    CAMPOS, CT
    HANSEN, BJ
    TUNA, N
    KARNEGIS, JN
    SANMARCO, ME
    AMPLATZ, K
    CASTANEDAZUNIGA, WR
    HUNTER, DW
    BISSETT, JK
    WEBER, FJ
    STEVENSON, JW
    LEON, AS
    CHALMERS, TC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) : 946 - 955
  • [8] PLATELET-FUNCTION IN HYPERLIPOPROTEINEMIA
    CARVALHO, AC
    COLMAN, RW
    LEES, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1974, 290 (08) : 434 - 438
  • [9] CLOFIBRATE REVERSAL OF PLATELET HYPERSENSITIVITY IN HYPERBETALIPOPROTEINEMIA
    CARVALHO, AC
    COLMAN, RW
    LEES, RS
    [J]. CIRCULATION, 1974, 50 (03) : 570 - 574
  • [10] BENEFICIAL-EFFECTS OF COLESTIPOL-NIACIN ON CORONARY ATHEROSCLEROSIS - A 4-YEAR FOLLOW-UP
    CASHINHEMPHILL, L
    MACK, WJ
    POGODA, JM
    SANMARCO, ME
    AZEN, SP
    BLANKENHORN, DH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (23): : 3013 - 3017